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Introduction {#sec001}
============

Wobbly possum disease (WPD) virus (WPDV) causes a fatal neurological disease of the common brushtail possum *(Trichosurus vulpecula*) and is classified within the order *Nidovirales* in the family *Arteriviridae* \[[@pone.0237091.ref001], [@pone.0237091.ref002]\]. Until recently, the virus had only been confirmed in captive and free-living possum populations in New Zealand, where it has been comprehensively studied, including in experimental infection trials \[[@pone.0237091.ref003]\]. Clinically, the disease is characterised by early behavioural changes followed by progressive cachexia and development of neurological signs such as intentional tremors, ataxia, difficulties climbing, and occasionally presumed blindness \[[@pone.0237091.ref002]--[@pone.0237091.ref004]\]. A similar clinical syndrome has more recently been described in common brushtail possums in Tasmania, while another syndrome, characterised predominantly by blindness, has been observed on mainland Australia \[[@pone.0237091.ref005]\]. These disease syndromes in Australian possums have not yet been extensively studied, however, two divergent WPDV sequences were recently identified in archival tissue samples from three out of nine clinically affected possums originating from New South Wales \[[@pone.0237091.ref005]\]. The hallmark histologic lesion in WPDV-affected possums in New Zealand is the presence of variable size infiltrates of mononuclear inflammatory cells in multiple tissues including liver, spleen, kidneys, choroids and brain \[[@pone.0237091.ref004], [@pone.0237091.ref006]\]. On mainland Australia however, where blindness is predominantly observed, the pathology described in possums presumably affected by WPD is a non-suppurative inflammation primarily limited to the brain, choroids and optic tract \[[@pone.0237091.ref005]\]. Genetic analysis of the available WPDV genomes has demonstrated that the two newly identified Australian WPDV viruses clustered together with the New Zealand virus and were between 71 and 74% identical to each other and to the New Zealand variant over an 1,787 aa region comprising a conserved RdRp protein \[[@pone.0237091.ref005]\]. The existence of such diverse WPD viruses, possibly even representing separate species, is reminiscent of the situation observed for simian haemorrhagic fever arteriviruses that circulate among various non-human primates in Africa \[[@pone.0237091.ref007]\] and suggests that some WPDV variants may still remain undiscovered. Based on the available data, WPDV appears to have separated early in the evolution from the current members of the family *Arteriviridae* \[[@pone.0237091.ref005], [@pone.0237091.ref008]\], suggesting that it may have co-evolved with its possum host. If so, WPDV was most likely brought to New Zealand at the time when possums were introduced from their native Australia in the late 1800s \[[@pone.0237091.ref009]\]. Despite its likely origins, WPDV in Australian possums is not well understood. The aim of the study was to screen Australian possums for evidence of exposure to WPDV, in order to better understand the biology and epidemiology of WPDV in Australia and its distribution across different geographical regions and different possum species. This study was performed as part of a larger project that aimed to identify a range of infectious agents in Australian possums.

Materials and methods {#sec002}
=====================

Ethics {#sec003}
------

The study and sampling protocol were approved by Zoos Victoria Animal Ethics Committee (project code ZV16007) and the University of Melbourne's Faculty of Veterinary and Agricultural Sciences Animal Ethics Committee (project code \#1613904.1). Sampling was performed with a Wildlife Act 1975 research permit from the Victorian Department of Environment, Land, Water and Planning (permit no. 10008226). The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to.

Sources of samples {#sec004}
------------------

Samples were opportunistically collected from four sources: 1) wild common ringtail possums (*Pseudocheirus peregrinus*, 55 serum and 89 spleen samples from 99 possums) or common brushtail possums (74 serum and 81 spleen samples from 104 possums) that presented to wildlife veterinary hospitals located in the Melbourne (Victoria) area between January 2016 and April 2018; 2) spleen samples collected from euthanised or naturally deceased common ringtail (n = 14) and common brushtail (n = 7) possums that presented to veterinary hospitals in north Sydney (New South Wales) between 2016 and 2017; 3) archival serum samples from wild common brushtail (n = 25) and common ringtail (n = 2) possums that presented to the veterinary hospital at Adelaide zoo (South Australia) between April 2013 and November 2017; and 4) archival serum samples from wild caught, apparently healthy mountain brushtail possums (*Trichosurus cunninghami*, n = 31) and one common brushtail possum, collected between 2005--2007 and 2014--2017 from the Strathbogie Ranges, Victoria \[[@pone.0237091.ref010], [@pone.0237091.ref011]\]. Altogether, 188 serum samples and 191 spleen samples from 283 possums were available for testing. Where possible, information regarding age, sex and environment the possum originated from (urban, semi-urban or rural) was recorded for each sample. For simplicity, the sampling areas were characterised by their most prominent environment. In the case of the Victorian samples, "urban" was defined as a semi-circular area bounded by Melbourne's main metropolitan ring road and encompassing the majority of the most heavily built up areas. Samples from Greater Melbourne that were collected outside this area were defined as "semi-urban", whilst those from the Strathbogie Ranges were defined as "rural". Samples from South Australia and New South Wales were collected from urban areas in Adelaide and Sydney respectively.

Sample collection {#sec005}
-----------------

Peripheral blood (0.5 to 2 mL) was collected into plain blood collection tubes under isoflurane general anaesthesia. Serum was separated from the clotted blood by low-speed centrifugation and stored at either -20 °C or -80 °C until testing. Aliquots were shipped to Massey University for WPDV antibody detection using ELISA. Spleen samples were collected at necropsy from fresh, chilled or previously frozen carcasses of possums that were either euthanised or had died for reasons unrelated to this study. The samples were placed in sterile 2 mL microcentrifuge tubes and frozen at -80 °C. Small (less than 0.5 mm in each dimension) pieces of spleen were later dissected from each sample after thawing, submerged in 10 x volume of RNA*later*^®^ solution (Invitrogen, USA) and shipped on ice blocks to Massey University for WPDV specific reverse transcriptase quantitative PCR (RT-qPCR) testing.

WPDV serology {#sec006}
-------------

Serum samples were tested for the presence of WPDV antibodies using an indirect ELISA based on a recombinant nucleocapsid (rN) protein of the virus. Sera were diluted 1:10 in phosphate buffered saline pH 7.5 containing 0.05% (v/v) Tween 20 (PBST) and tested in duplicate according to the protocol described previously \[[@pone.0237091.ref012]\], with the exception that substrate development was stopped after 3--5 minutes, based on the strength of the colour in positive control wells. The results were presented as corrected optical density at 450 nm (OD~450~). Previously established cut-off values were used to classify samples as negative (OD~450~ \< 0.28), suspect or equivocal (OD~450~ = 0.28--0.41) or positive (OD~450~ \> 0.41) for WPDV antibodies \[[@pone.0237091.ref012]\]. As the rN antigen used in the blocking ELISA test was based on the sequence of the New Zealand WPDV, the predicted amino acid sequences of nucleocapsid (N) protein from the newly available two Australian WPD viruses were aligned with that of the New Zealand WPDV. The multiple alignments were performed using Clustal Omega (version 1.2.4) with default settings (available at <https://www.ebi.ac.uk/Tools/msa/clustalo/>).

WPDV specific qRT-PCR {#sec007}
---------------------

Viral RNA was extracted from approximately 10 mg of spleen using the NucleoMag^®^ Vet kit (MACHEREY-NAGEL, Germany) on a KingFisher^™^ Flex Purification System, according to the manufacturer's instructions, and eluted with 100 μL of the supplied elution buffer. Complementary DNA (cDNA) was made using 2 μL qScript^™^ Supermix (Quanta Biosciences, USA) and 8 μL RNA in a 10 μL reaction, according to the manufacturer's instructions. Spleen samples (n = 191) were tested in duplicate on a Mic qPCR instrument (Bio Molecular Systems), using 1 μL template and PowerUp^™^ SYBR^®^ Green Master Mix (Applied Biosystems, USA), with the primer concentration and cycling conditions as described previously \[[@pone.0237091.ref013]\]. Primers targeted the RNA dependent RNA polymerase gene within ORF1b \[[@pone.0237091.ref013]\]. Samples were considered positive if the amplification curve crossed the automatically defined threshold and the melting peak was between 85 °C and 86.5 °C. Samples were considered equivocal if only one of the duplicates was positive with the Cq value \>33 or if both duplicates showed the correct melting peak, but the Cq was \>37. Samples with equivocal results were retested in duplicate with 2 μL and 5 μL template, using a conventional PCR targeting a 321 bp conserved region in ORF1b \[[@pone.0237091.ref014]\].

Statistical analysis {#sec008}
--------------------

Statistical analysis was carried out using Stata/SE 14.2 (StataCorp, USA). Frequency of WPDV antibody detection was calculated as the proportion of seropositive animals in the study population, with exact 95% confidence intervals (CI). Fisher's exact test was used to test for differences in seroprevalence by species, sex, age and environment. The analysis was run twice, using both the higher (\> 0.41) and lower (\> 0.28) ELISA cut-off values for sample positivity. Adjustment for test imperfection to estimate true prevalence was performed using the Rogan-Gladen estimator, based on previously determined estimates for test sensitivity and specificity \[[@pone.0237091.ref012], [@pone.0237091.ref015]\].

Results {#sec009}
=======

Serology {#sec010}
--------

Approximately half of the serum samples came from common brushtail possums. Adults, males and possums from urban areas were over-represented in the sampled population ([Table 1](#pone.0237091.t001){ref-type="table"}). Thirty out of 188 serum samples (16.0%, 95% CI 11.0--22.0) tested positive for WPDV antibodies, while a further 22/188 (11.7%, 95% CI 7.5--17.2) were equivocal. The remaining 136 serum samples were negative for WPDV antibodies. Adjusting for test imperfection, the true seroprevalence of WPDV in this sample set would be 22.0% (95% CI 14.2--32.0%). Seropositive, equivocal and seronegative individuals were identified amongst both the recently collected and archival samples, including the mountain brushtail samples from 2006 (2/14 seropositive and 2/14 equivocal). The percentage of WPDV seropositive possums stratified by species and geographical area is shown in Figs [1](#pone.0237091.g001){ref-type="fig"} and [2](#pone.0237091.g002){ref-type="fig"}. WPDV seropositivity was comparable between groups based on sex, age, environment and species using the higher (\> 0.41) cut-off value for positive samples ([Table 1](#pone.0237091.t001){ref-type="table"}). When the lower (\> 0.28) cut-off value was used, common brushtail possums had higher seropositivity than possums from the other two species (p = 0.001), and the WPDV seropositivity was higher after possums reached adulthood (p = 0.026; [S1 Table](#pone.0237091.s001){ref-type="supplementary-material"}).

![The percentage of possums seropositive for antibodies to WPDV in Australia, stratified by species.\
Samples were considered positive if their corrected OD~450~ \> 0.41 and equivocal if 0.28 \< corrected OD~450~ ≤ 0.41. Sera (n = 188) were obtained from wild-caught, apparently healthy possums (archival samples) or injured/sick possums presented to wildlife centres in various geographical regions in Australia. Bar plots showing the percentage of seropositive samples in A and including both seropositive and equivocal samples in B, with 95% confidence intervals.](pone.0237091.g001){#pone.0237091.g001}

![Geographical distribution of sampled possums that were seropositive or suspect seropositive for WPDV in Australia.\
Sera (n = 188) originated from five regions in the states of Victoria and South Australia: A- Adelaide; B---Werribee; C---Melbourne zoo; D---the eastern suburbs of Melbourne and the Yarra Valley; E---Strathbogie mountains. Seropositivity for wobbly possum disease virus (WPDV) was defined by a corrected OD~*450*~ \> 0.41 and suspect positives (equivocal) by a corrected OD~450~ \> 0.28. Base maps and state boundaries were sourced from GEODATA TOPO 250K Series 3 (Geoscience Australia; <http://pid.geoscience.gov.au/dataset/ga/64058> accessed 28 July 2019) and reproduced under Creative Commons Attribution License 4.0.](pone.0237091.g002){#pone.0237091.g002}

10.1371/journal.pone.0237091.t001

###### Seroprevalence results and statistical analysis assessing individual epidemiological variables for wobbly possum disease virus seropositivity in a sample of Australian possums (n = 188), using the cut-off value of corrected OD~450~ \> 0.41 for positive samples.

![](pone.0237091.t001){#pone.0237091.t001g}

                         *WPDV seropositive*   *Prev. (%)*   *95% CI*     *p value*[\*](#t001fn001){ref-type="table-fn"}
  ---------------------- --------------------- ------------- ------------ ------------------------------------------------
  ***Species***                                                           0.38
  *Common ringtail*      6/57                  10.5          4.0--21.5    
  *Mountain brushtail*   5/31                  16.1          5.5--33.7    
  *Common brushtail*     19/100                19.0          11.8--28.1   
  ***Sex***                                                               0.84
  *Male*                 17/106                16.0          9.6--24.4    
  *Female*               13/75                 17.3          9.6--27.8    
  *Unknown*              0/7                   0.0           0.0--41.0    
  ***Age***                                                               0.16
  *Juvenile*             5/32                  15.6          5.3--32.8)   
  *Subadult*             1/26                  3.9           0.1--19.6    
  *Adult*                24/126                19.1          12.6--27.0   
  *Unknown*              0/4                   0.0           0.0--60.2    
  ***Environment***                                                       1.00
  *Rural*                5/32                  15.6          5.3--32.8    
  *Urban*                15/91                 16.5          9.5--25.7    
  *Semi-urban*           10/65                 15.4          7.6--26.5    

\* calculated using Fisher's exact test, excluding the unknown groups

The comparison of predicted protein N sequences of the Australian and New Zealand WPD viruses showed that the Australian aa sequences were about 70% identical to the sequences from the New Zealand virus ([Fig 3](#pone.0237091.g003){ref-type="fig"}).

![Multiple alignment of the predicted protein N sequences of the New Zealand and Australian Wobbly Possum Disease Viruses (WPDVs).\
The alignments were done in Clustal Omega using default parameters. The regions used for the alignments comprised nucleotides 12241--12627 (WPDV-AU1, GenBank accession MN635447), 12017--12403 (WPDV-AU1, GenBank accession MN635448) and 12424--12804 (WPV-NZ, GenBank accession number JN116253. The percent identity values are also shown.](pone.0237091.g003){#pone.0237091.g003}

WPD RT-qPCR {#sec011}
-----------

A total of 191 spleen samples were tested for WPDV using RT-qPCR. Of these, 35 samples were considered equivocal. However, all of these were negative when tested with the conventional PCR, and hence all 191 samples tested were considered negative for WPDV RNA.

Discussion {#sec012}
==========

This study is the first to demonstrate antibodies to a WPDV, or an antigenically similar virus, in Australian possums. At least 16.0% of sampled possums had WPDV antibody using the rN ELISA test. The use of rN protein as antigen in this ELISA was informed by previous studies showing this protein to be immunodominant in other arteriviruses \[[@pone.0237091.ref016]--[@pone.0237091.ref018]\]. The immunogenicity of this protein in WPD has been demonstrated in experimentally infected possums in a previous study using the same ELISA method and antigen \[[@pone.0237091.ref012]\]. In addition, WPDV N protein has no similarity to any other proteins currently deposited in public databases based on BLAST searches. The predicted N proteins from recently characterised Australian WPD viruses were approximately 70% identical to the rN protein used as an antigen in the blocking ELISA test. This is a substantial level of identity; however, the impact these sequence differences may have on the detection of antibodies to the different viruses is not known. Considering these observations, our data provide strong evidence that WPDV, or antigenically similar viruses, circulate among Australian possum species.

The cut-off value of OD~450~ \> 0.41 used for positive samples was previously shown using Bayesian latent class analysis \[[@pone.0237091.ref012]\] to have a sensitivity of 0.62 and specificity of 0.97, while the sensitivity and specificity using the lower cut-off (OD~450~ \> 0.28) was 0.79 and 0.84, respectively. The establishment of the cut-offs was hindered by the lack of known negative sera \[[@pone.0237091.ref012]\]. In this study, we initially elected to use the more conservative, higher cut-off with a higher specificity and less likelihood of false positive results. However, due to the uncertainty surrounding these cut-off values, the potential for misclassification bias needs to be considered when interpreting the results and, consequently, the results in this study were re-analysed using the lower cut-off for completion. Nonetheless, even after adjusting for test imperfection and using the most conservative cut-off, our estimate of the true seroprevalence of WPDV (22.0%; 95% CI 14.2--32.0%) provides strong evidence that the virus is present and circulating in the country. The detection of seropositive individuals from regional Victoria in 2006 would support this finding. The potential degradation of sample quality related to long-term storage and repeated freeze-thaw cycles of historical samples is worthy of consideration, particularly with regards to the equivocal results for some samples; however, other studies have demonstrated that antibodies are relatively robust to such changes \[[@pone.0237091.ref019]--[@pone.0237091.ref021]\].

The proportion of seropositive possums in Australia (16.0% positive and 11.7% equivocal) was similar to that reported in New Zealand (20.9% positive and 11.7% equivocal) using the same ELISA \[[@pone.0237091.ref012]\]. This is unexpected, considering that New Zealand and Australian possums live in very different environments, with New Zealand possums (which are considered pests \[[@pone.0237091.ref022]\]) existing in large numbers \[[@pone.0237091.ref023]\] and in high densities, which could facilitate the transmission of WPDV \[[@pone.0237091.ref003]\]. The density of possums in the Australian sampling locations was presumably lower, but possum home range can increase with the decrease in possum density \[[@pone.0237091.ref024]\], potentially facilitating similar levels of contact between possums in populations of various densities, thereby contributing to a similar proportion of seropositive animals in New Zealand and Australian-based studies. Previous research and infection studies have suggested that WPDV can be transmitted through direct or indirect contact, either with infected individuals or surfaces contaminated with body secretions from infected animals, although the exact routes of natural transmission have not been fully elucidated \[[@pone.0237091.ref003], [@pone.0237091.ref025]\]. Documented modes of transmission of other arteriviruses include contact with infected individuals, fomites or aerosols from infective body secretions, as well as venereal and *in utero* transmission \[[@pone.0237091.ref026]--[@pone.0237091.ref028]\]. The possibility that WPDV could be mechanically transmitted by flying insects, prevalent in Australia, should also be considered in future studies \[[@pone.0237091.ref029], [@pone.0237091.ref030]\].

We have also shown for the first time that antibodies to WPDV, or an antigenically similar virus, are present in possums other than common brushtails, including common ringtail possums and mountain brushtail possums. Australia is home to more than 20 possum species, as well as many other marsupials \[[@pone.0237091.ref031]\]. Hence, it would be of value to determine the full spectrum of susceptibility to WPDV infection of various marsupial species. Such data would be useful to better understand the ecology of the virus in Australia and its clinical implications, as well as to help inform disease intervention or management strategies (such as management of captive breeding colonies or translocation risk analyses) for endangered possum species.

The design of the current study did not allow associations between WPDV infection and disease to be investigated. This was due to the opportunistic sampling strategy employed, with the majority of samples obtained from diseased or deceased possums and no opportunities for obtaining paired samples to demonstrate rising antibody titres. Collection of tissues for concurrent histological examination could be considered in future studies to look for associated pathology, but these were not available for this sample set.

WPDV RNA was not detected by PCR in this study. This could indicate that the virus was genetically divergent from the New Zealand WPDV, although both sets of primers used in this study were designed to target well conserved regions of the nidovirus genome \[[@pone.0237091.ref013], [@pone.0237091.ref014]\]. The pairwise nucleotide similarities between the two Australian WPDV sequences (WPDV AU1 and WPDV AU2) and the New Zealand WPDV sequence were approximately 71% over the entire genome, suggesting a comparatively high level of sequence divergence between different lineages of WPDV \[[@pone.0237091.ref005]\]. Retrospective comparison of the Australian and New Zealand WPDV sequences within the regions targeted by the PCR primers used in the current study suggested that the qPCR primers may not have been able to detect all variants of WPD viruses, as there were three (WPDV AU1) and four (WPDV AU2) mismatches within the forward primer, as well as four (WPDV AU1) and 7 (WPDV AU2) mismatches within the reverse primer. However, the conventional PCR primers would have been expected to bind to both WPDV AU1 and AU2 sequences, as there were only two (forward primer) or one (reverse primer) mismatches between the New Zealand and Australian WPDV sequences, with full complementarity in the last three nucleotides at the 3' end.

Alternatively, failure to detect WPDV RNA in the current study could be attributed to the timing of sample collection with respect to WPDV infection. In experimentally infected possums in New Zealand, high levels of WPDV have been detected in multiple organs three to four weeks following infection, including in serologically positive possums \[[@pone.0237091.ref025]\]. However, the persistence of virus in naturally infected possums may be different, and there may be differences between virus lineages. Poor sample quality may have also prevented detection of viral RNA in the opportunistically collected samples, particularly after multiple freeze-thaw cycles prior to shipment and RNA extraction. Furthermore, many of the samples were collected a few days after death, which would likely have affected viral RNA quality. Future attempts to detect or isolate WPDV should therefore target a range of fresh tissues, particularly those previously found to contain high concentrations of the virus (e.g. liver, brain, spleen, lymph nodes or kidneys), with careful attention to tissue preservation and handling \[[@pone.0237091.ref013]\]. Availability of more viral sequences from field WPDVs circulating in different regions of New Zealand and Australia would shed some light on the evolutionary pathways of the virus in these two diverse environments.

Supporting information {#sec013}
======================

###### Seroprevalence results and statistical analysis assessing individual epidemiological variables for wobbly possum disease virus seropositivity in a sample of Australian possums (n = 188), using the cut-off value of corrected OD~450~ \> 0.28 for positive samples.
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The manuscript is technically sound and the data support the conclusions. Nonetheless, the authors make it clear that another paper has been published describing the disease syndrome in Australia (citation below). The findings of the recent publication on the topic have not incorporated in the submitted manuscript introduction and are not fully woven into the discussion. This approach leaves the reader quite isolated and not updated on the current breadth of knowledge on the disease syndrome either in the NZ nor the Australian context. A more detailed introduction summarising the similarities and differences between Australian and New Zealand wobbly possum disease, including concise descriptions of the temporal, geographic range s, putative aetiologic agents identified and comparative pathology would ensure readers have a wholistic understanding of the context for the investigation described.

Recent citation:

Chang, W., Eden, J., Hartley, W.J. et al. Metagenomic discovery and co-infection of diverse wobbly possum disease viruses and a novel hepacivirus in Australian brushtail possums. One Health Outlook 1, 5 (2019). <https://doi.org/10.1186/s42522-019-0006-x>

\-\--

Line 46 -- summarising the histopathology -- should include choroid and optic tract, should indicate that the histological lesions vary regionally (CNS only on mainland Australia, and multisystemic LP inflammation in NZ and Tas)

Line 50 -- The sequence of emergent literature is not highly relevant to the reader. The readership would benefit more from an understanding of the current knowledge of the variation across the genomes of the New Zealand and two Australian arteriviruses associated with the disease syndrome described. Understanding the diversity across the three arteriviruses found within wobbly possums seems to be an important basis for interpreting serological responses. A brief summary of the temporal, geographic, and demographic nature of the syndrome in Australia would also benefit the reader and introduce the value of the serological study described.

Line 67 delete different

Line 90, perhaps euthanased or died for reasons unrelated to this study (delete naturally from various causes)

Line 144 Figure 1 and 2 rather than Fig -- within the text

Line 164-166 better placed in the materials and methods

Line 170 and elsewhere -- univariate seems more universally applied term rather than univariable

Line 186 -- However it is currently unknown which proteins provide the main targets -- could be worded in a more natural manner

Line 188-89 -- May sound more natural by altering the position of the final phrase. Nonetheless, experimentally infected possums showed an increase in corrected OD450 values, using the same antigen, within four weeks....

Line 182 -- first line of the discussion describes WPDV as a single entity, when three arteriviruses have been associated with the syndrome and this is important to understand when interpreting likely antigenic similarities and cross reactivity for a test designed for the New Zealand genotype - 70+% genomic divergence

Line 194-196 -- The sentence does not make it clear how the findings of prevalence relate to the length of time that the syndrome and disease agents have been in the country. The citations here, do not include the most recent published report by Chang et al, where the temporal distribution of the syndrome is most thoroughly described.

Line 198 -- change has been to were

Line 202 -- perhaps consider rewording "This is interesting" as it seems a bit presumptive to assume what the reader may find interesting

Line 222-224 -- Although samples were collected opportunistically, histological samples could have also been taken from the dead animals examined. Lymphoplasmocytic inflammation often persists through freeze-thaw artefact.

Line 224 -- the language seems awkward and the premise that a single titre could ever tell you when an infection occurred seems flawed

Line 230 -- it is difficult to understand how the reader could interpret the PCR findings without having knowledge of the presence of the three arteriviruses associated with wobbly possum syndrome and the extent of their genomic divergence. It seems very late to be introducing the presence and diversity of the three arteriviruses in line 239-240 -- when describing primers

Line 240 -- delete used

Reviewer \#2: Thanks for the opportunity to review this article. It was very well written and interesting, with measured and scientifically appropriate interpretation. My main comments are in regards to model structure and the Figures.

Major comments:

Granted, the statistical approach used here is far better than the usual standard of wildlife publications, which is encouraging. However, the manual backwards stepwise elimination approach is an outdated method for estimating causal effects. A minimum approach should involve each risk factor considered separately in its own model, with covariates added in consideration of causal framework.

The figures should be constructed better for effective communication. A few suggestions:

\- for Figure 1, it would be helpful to the reader to present the plots unstacked and with error margins: particularly in view of the relatively small sample sizes, error margins are essential for a reader to readily identify whether or not the seroprevalence differs between the species.

\- Figure 2 is unlikely to print well given its large overall size and the relatively small pie charts; and indeed the use of pie charts is to be avoided (pie charts are a poor medium for comparing outcomes across groups). While a map of source sites is good idea, it could be communicated with a small map of Australia and icons for all sample sources, including north Sydney (omit the pie charts). The comparison of the serological outcome between sample sites could then be presented as a separate figure, in a bar chart with error margins (for the same reasons as Figure 1).

Minor comments:

Lines 29-30: Provide error margins with the proportions.

Line 39: Suggest replacing 'Australian brushtail possum' with 'common brushtail possum': it's best to use the same common name consistently throughout the article. It could also be confusing for readers not familiar with Australian and New Zealand fauna, given the geographical references involved in the sentence too.

Line 74- 79: Given the age of some of the serum samples, it would be appropriate for brief commentary in the discussion on how that may have affected results in the discussion. It would also be interesting to know amongst relatively old samples, if both seropositives and seronegatives were detected- a sentence or two in the Results would suffice.

Line 81: Indicate the criteria used to define a possum as being urban, semi-rural or rural.

Line 131-132: The approach of modelling the 'suspect/equivocal' results in addition to the seropositive results was unusual, but I can understand why given that cut-offs are poorly defined. Some brief, specific commentary in the discussion on the reasoning and the potential implications of misclassification bias would be appropriate. Further, a mention of the relatively small sample size and potential for Type II error influencing study findings is required.

Line 137: It would be helpful to start the Results section with an overall summary of the possum origin of the samples, separately for ELISA and PCR samples. E.g. summarise the numbers of possums by sample source, species, sex, age and environmental origin.

Line 173: Table 1: provide error margins for the prevalence estimates

Line 194-197: Estimates of true prevalence belong in the Results section, with methods for estimation outlined in the Methods section.

Line 199-200: Or more realistically, latent class analysis could be used to estimate prevalence using imperfect tests - identification of 'known negative' sera of a poorly understood wildlife infection is not the practical approach. This sentence should be updated accordingly.

Line 202- 211: To complement this section, a brief comment on known modes of transmission for other arteriviruses in other species would be informative to the reader.

Line 216-219: Vague commentary like this whilst referencing endangered species is not particularly helpful. How would better understanding the ecology of the virus in Australia and its clinical implications be of value, beyond academic interest? Endemic diseases are not the primary cause of species declines in Australia, so understanding the ecology of the virus and its clinical implications to inform development of interventions to target endemic disease is not a particularly effective or efficient way to aide species recovery. So for what other reason(s) might understanding the ecology of the virus and its clinical implications be helpful for endangered wildlife? Specify clearly or consider omitting this part of the text.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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PLOS ONE

Dear Dr. Tolpinrud,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, reviewer 2 has provided feedback requiring minor changes to the manuscript.

Please submit your revised manuscript by August 16, 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Michelle L. Baker, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for the opportunity to further review the manuscript.

The authors have done an excellent job addressing the suggestions of both reviewers. Changes have been thoughtful, clear and concise. The table titles and figures are thoughtfully enhanced. In my opinion the manuscript is acceptable for publication. I offer very minor suggestions, which include:

\- Describing the results from the NSW animals - I am certain that there would be interest from the readership

\- Line 85 -- Wild does not need to be capitalised

\- Line 100 -- divided -- perhaps classified or characterised might read better

\- Line 236 -- circulates -- to circulate

\- Line 241- The establishment of the cut-offs was (rather than were) hindered

\- Line 267 -- although the exact routes of natural transmission have (rather than has) not been fully elucidated

\- Line 316 -- found to contain high concentrations (rather than concentration)

Reviewer \#2: A couple of minor comments:

Lines 250: "As the authors do not suggest a single optimal cut-off, it is unclear which is most appropriate for our purpose". This statement comes across poorly, as it vaguely insinuates criticism the validation study for not dictating a one-size-fits-all "optimal cut-off", which would be entirely inappropriate. The optimal cut-off will depend on the circumstances of the use of the test; specifically, the relative importance of sensitivity and specificity. It is most definitely up to the study authors to decide on the most appropriate cut-off a priori, and consider the ramifications of that choice in interpreting findings. A minor tweak of the wording in view of this would be appropriate.

Line 256-257 "our estimate of true seroprevalence of WPDV (22.0%; 95% CI 14.2 -- 32.0%) supports the view that this virus has been present and circulating for some time". This statement is too tenuous and ambiguous; I would recommend citing only the more specific evidence of identification of seropositive individuals amongst samples from 2006.

Line 298: matching could be used as part of the design of an investigation into associations between the infection and disease, but it is not essential and so does not deserve specific attention here.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

The authors have done an excellent job addressing the suggestions of both reviewers. Changes have been thoughtful, clear and concise. The table titles and figures are thoughtfully enhanced. In my opinion the manuscript is acceptable for publication. I offer very minor suggestions, which include:

Describing the results from the NSW animals - I am certain that there would be interest from the readership

Authors' response: Unfortunately only spleen samples were available from NSW (line 89-91). As all of the spleen samples tested in this study were negative for WPDV RNA, the NSW samples are covered under the WPD RT-qPCR results (line 218-221).

Line 85 -- Wild does not need to be capitalised

Line 100 -- divided -- perhaps classified or characterised might read better

Line 236 -- circulates -- to circulate

Line 241- The establishment of the cut-offs was (rather than were) hindered

Line 267 -- although the exact routes of natural transmission have (rather than has) not been fully elucidated

Line 316 -- found to contain high concentrations (rather than concentration)

Authors' response: Thank you for these corrections -- we have updated the manuscript to include all of these changes. 

Reviewer \#2:

Lines 250: "As the authors do not suggest a single optimal cut-off, it is unclear which is most appropriate for our purpose". This statement comes across poorly, as it vaguely insinuates criticism the validation study for not dictating a one-size-fits-all "optimal cut-off", which would be entirely inappropriate. The optimal cut-off will depend on the circumstances of the use of the test; specifically, the relative importance of sensitivity and specificity. It is most definitely up to the study authors to decide on the most appropriate cut-off a priori, and consider the ramifications of that choice in interpreting findings. A minor tweak of the wording in view of this would be appropriate.

Authors' response: The sentence "As the authors of that prior study do not suggest a single optimal cut-off, it is unclear which is most appropriate for our purpose" has been changed to "In this study, we initially elected to use the more conservative, higher cut-off with a higher specificity and less likelihood of false positive results. However, due to the uncertainty surrounding these cut-off values, the potential for misclassification bias needs to be considered when interpreting the results and, consequently, the results in this study were re-analysed using the lower cut-off for completion."

Line 256-257 "our estimate of true seroprevalence of WPDV (22.0%; 95% CI 14.2 -- 32.0%) supports the view that this virus has been present and circulating for some time". This statement is too tenuous and ambiguous; I would recommend citing only the more specific evidence of identification of seropositive individuals amongst samples from 2006.

Authors' response: We have removed the speculative suggestion that it has been circulating "for some time" and the sentence has been changed to: "our estimate of the true seroprevalence of WPDV (22.0%; 95% CI 14.2--32.0%) provides strong evidence that the virus is present and circulating in the country".

Line 298: matching could be used as part of the design of an investigation into associations between the infection and disease, but it is not essential and so does not deserve specific attention here.

Authors' response: We have reworded the sentence slightly to remove the mention of matching and the paragraph now reads: "The design of the current study did not allow associations between WPDV infection and disease to be investigated. This was due to the opportunistic sampling strategy employed, with the majority of samples obtained from diseased or deceased possums and no opportunities for obtaining paired samples to demonstrate rising antibody titres. Collection of tissues for concurrent histological examination could be considered in future studies to look for associated pathology, but these were not available for this sample set".
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Dear Dr. Tolpinrud,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Michelle L. Baker, PhD

Academic Editor
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Dear Dr. Tolpinrud:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff
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